[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ: Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer; 2002 May 20;86(10):1555-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
  • The aim of this phase II study was to assess the efficacy and toxicity of a dose-dense alternating chemotherapy regimen in this subset of patients.
  • High volume non-seminomatous germ-cell tumours was defined as follows: at least two sites of non pulmonary metastases, an extragonadal primary tumour, a serum human chorionic gonadotropin level higher than 10 000 mIU x ml(-1), or a alpha-foetoprotein level higher than 2000 mIU ml(-1).
  • Forty-two patients (72.4%) had a complete response to therapy.
  • With a median follow-up time of 31 months, the 3-year progression-free survival rate was 71% (95% confidence interval, 60 to 84%) and the 3-year overall survival rate was 73% (95% confidence interval: 62 to 86%).
  • Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Anemia, Refractory, with Excess of Blasts / chemically induced. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dactinomycin / administration & dosage. Dactinomycin / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Prognosis. Prospective Studies. Remission Induction. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] comCopyright 2002 Cancer Research UK
  • [Cites] Crit Rev Oncol Hematol. 1996 Apr;22(3):229-63 [8793277.001]
  • [Cites] Cancer. 1977 Apr;39(4):1372-81 [856437.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1031-40 [2453619.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Bull Cancer. 1990;77(2):169-80 [2156588.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5904-10 [1697503.001]
  • [Cites] Ann Oncol. 1991 Mar;2(3):197-202 [1710481.001]
  • [Cites] Ann Oncol. 1991 Mar;2(3):203-11 [1710482.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1163-72 [1710655.001]
  • [Cites] Eur Urol. 1992;21(4):287-93 [1333957.001]
  • [Cites] Eur Urol. 1993;23(1):213-7; discussion 218 [8386652.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):283-92 [7799032.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):87-92 [7528272.001]
  • [Cites] Eur J Cancer. 1994;30A(11):1607-11 [7530470.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] Ann Oncol. 1997 May;8(5):477-83 [9233528.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):692-701 [9469359.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):725-32 [9469363.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):799-800 [9469373.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):828-32 [9743309.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):289-93 [10355572.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3450-6 [10550141.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):133-49 [10761747.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1115-20 [11061604.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):203-9 [6197154.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1029-35 [6198064.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):326-35 [2579213.001]
  • [Cites] Am J Med. 1986 Aug;81(2):219-28 [2426944.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2534-41 [11331333.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1460-7 [11745223.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):125-34 [11863094.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • (PMID = 12085204.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; BOP-CISCA-POMB-ACE regimen
  • [Other-IDs] NLM/ PMC2746595
  •  go-up   go-down


2. Ohdo S: Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs. J Pharmacol Sci; 2007 Feb;103(2):155-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs.
  • The effectiveness and toxicity of antitumor drugs vary depending on dosing time associated with the 24-h rhythms of biochemical, physiological, and behavioral processes under the control of the circadian clock.
  • Such chronopharmacological phenomena are influenced by not only the pharmacokinetics but also pharmacodynamics of medications.
  • For example, the antitumor effect and/or toxicity of irinotecan hydrochloride, interferon, and antiangiogenic agents vary depending on the dosing time associated with the 24-h rhythm of their target enzyme, receptor, protein, and pharmacokinetics.
  • Chronotherapy is especially relevant when the risk and/or intensity of the symptoms of disease vary predictably over time.
  • In a randomized multicenter trial involving patients with previously untreated metastases from colorectal cancer, the chronomodulated infusion of oxaliplatin, fluorouracil (5-FU), and folinic acid is compared with a constant-rate infusion method.
  • Side effects such as stomatitis, peripheral sensory neuropathy are lower and the objective response is higher in the chronotherapy as compared with the fixed-rate infusion.
  • Although interferon (IFN) also alters the clock function, the disruptive effect of IFN on clock function can be overcome by devising a dosing regimen that minimizes adverse drug effects on clock function.
  • Thus one approach to increasing the efficiency of pharmacotherapy is the administration of drugs at times at which they are most effective and/or best tolerated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biological Clocks / genetics. Biological Clocks / physiology. Central Nervous System / physiology. Circadian Rhythm / genetics. Circadian Rhythm / physiology. Neoplasms / drug therapy. Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299245.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 23
  •  go-up   go-down


3. Viret F, Bertucci F, Genre D, Gravis G, Chabannon C, Conte M, Houvenaeghel G, Maraninchi D, Viens P: Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study. Bone Marrow Transplant; 2002 Dec;30(12):879-84
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.
  • From August 1995 to December 1997, 15 patients with stage III-IV ovarian cancer were treated with outpatient intensive chemotherapy with G-CSF and stem cell support.
  • Fourteen patients had stage IIIc and one patient had stage IV disease with liver metastases.
  • This pilot study shows that dose-dense chemotherapy with paclitaxel and carboplatin is associated with low toxicity and may improve the outcome of patients with poor prognosis ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease Progression. Disease-Free Survival. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematologic Diseases / chemically induced. Humans. Life Tables. Mesna / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peripheral Nervous System Diseases / chemically induced. Pilot Projects. Prognosis. Recombinant Proteins. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12476280.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; NR7O1405Q9 / Mesna; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


Advertisement
4. Morozova O, Vojvodic M, Grinshtein N, Hansford LM, Blakely KM, Maslova A, Hirst M, Cezard T, Morin RD, Moore R, Smith KM, Miller F, Taylor P, Thiessen N, Varhol R, Zhao Y, Jones S, Moffat J, Kislinger T, Moran MF, Kaplan DR, Marra MA: System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin Cancer Res; 2010 Sep 15;16(18):4572-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma.
  • PURPOSE: Neuroblastoma (NB) is an aggressive tumor of the developing peripheral nervous system that remains difficult to cure in the advanced stages.
  • The poor prognosis for high-risk NB patients is associated with common disease recurrences that fail to respond to available therapies.
  • NB tumor-initiating cells (TICs), isolated from metastases and primary tumors, may escape treatment and contribute to tumor relapse.
  • New therapies that target the TICs may therefore prevent or treat tumor recurrences.
  • EXPERIMENTAL DESIGN: We undertook a system-level characterization of NB TICs to identify potential drug targets against recurrent NB.
  • We used next-generation RNA sequencing and/or human exon arrays to profile the transcriptomes of 11 NB TIC lines from six NB patients, revealing genes that are highly expressed in the TICs compared with normal neural crest-like cells and unrelated cancer tissues.
  • RESULTS: Our study revealed that genes in the BRCA1 signaling pathway are frequently misexpressed in NB TICs and implicated Aurora B kinase as a potential drug target for NB therapy.
  • Treatment with a selective AURKB inhibitor was cytotoxic to NB TICs but not to the normal neural crest-like cells.
  • CONCLUSION: This work provides the first high-resolution system-level analysis of the transcriptomes of 11 primary human NB TICs and identifies a set of candidate NB TIC-enriched transcripts for further development as therapeutic targets.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplastic Stem Cells / pathology. Neuroblastoma / drug therapy. Neuroblastoma / pathology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] Aurora Kinase B. Aurora Kinases. Chromatography, Liquid / methods. Drug Evaluation, Preclinical. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Gene Knockdown Techniques. Humans. Microarray Analysis. Molecular Targeted Therapy / methods. Protein Kinase Inhibitors / therapeutic use. RNA, Small Interfering / pharmacology. RNA, Small Interfering / therapeutic use. Systems Biology / methods. Tandem Mass Spectrometry / methods. Therapies, Investigational / methods. Therapies, Investigational / trends. Validation Studies as Topic

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [ErratumIn] Clin Cancer Res. 2010 Dec 1;16(23):5914
  • (PMID = 20651058.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


5. Llarena Ibarguren R, Azurmendi Arín I, García-Olaverri Rodríguez J, Olano Grasa I, Canton Aller E, Pertusa Peña C: [Neurological metastases secondary to germ cell testicular tumor]. Arch Esp Urol; 2008 Oct;61(8):939-43
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurological metastases secondary to germ cell testicular tumor].
  • OBJECTIVE: Neurological metastases secondary to urological tumors account for 12% overall.
  • METHODS: We report one case of mixed germ cell tumor in a 49-year-old male patient treated with systemic chemotherapy during 18 months before presenting with severe central and peripheral neurological symptoms leading to death due to massive cerebral hemorrhage.
  • RESULTS: We describe three types of presentation of cerebral metastases in patients with testicular cancer.
  • Type I present synchronically with the primary tumor.
  • Type 2 are diagnosed after a period of remission after conventional cytostatic treatment.
  • Type 3 metastases are diagnosed during the course of the disease and its treatment.
  • CONCLUSIONS: Except unique metastases classified in groups 1 and 2, which are susceptible of surgery or radiosurgery, in which in response may be expected; the rest of lesions secondary to germ cell tumors have an ominous prognosis and outcomes, with short survivals.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / secondary. Nervous System Neoplasms / secondary. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040166.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P: Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol; 2005 Nov;16(11):1772-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
  • PURPOSE: The aim of this study was to characterize the prevalence and predictors of central nervous system (CNS) metastasis among women with HER2-overexpressing metastatic breast cancer receiving trastuzumab-based therapy.
  • METHODS: The frequency and time course of isolated CNS progression were characterized among women with HER2-positive metastatic breast cancer, receiving chemotherapy with or without trastuzumab as first-line treatment for metastatic disease in two clinical trials.
  • The first trial was a multicenter randomized phase III study of chemotherapy (doxorubicin/cyclophosphamide or paclitaxel) +/- trastuzumab, and the second was a multicenter phase II trial of vinorelbine + trastuzumab.
  • All patients had measurable disease and were free of symptomatic CNS disease at initiation of study treatment.
  • RESULTS: Nearly 10% of patients receiving trastuzumab in combination with chemotherapy developed isolated CNS metastases as first site of tumor progression.
  • Progression in the CNS tended to be a later event than progression at other sites among women receiving trastuzumab-based therapy.
  • Trastuzumab-based treatment did not substantially delay onset of CNS metastases as initial site of progression.
  • CONCLUSIONS: Patients with HER2-overexpressing metastatic breast cancer are at risk for isolated CNS progression, reflecting improved peripheral tumor control and patient survival through use of trastuzumab-based therapy, and a relative lack of CNS activity with trastuzumab.
  • Better treatments for CNS recurrences are needed.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150805.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  •  go-up   go-down


7. Suyama T, Ueda T, Fukasawa S, Imamura Y, Nakamura K, Miyasaka K, Sazuka T, Egoshi K, Nihei N, Hamano M, Ichikawa T, Maruoka M: Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol; 2009 Apr;39(4):244-50
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
  • OBJECTIVE: The aim of this study was to evaluate the efficacy and toxicities of the gemcitabine and paclitaxel combination regimen as second-line chemotherapy for patients with advanced or metastatic urothelial carcinoma (UC) who have previously been treated with platinum-based chemotherapy for the metastatic disease.
  • METHODS: Thirty-three patients with advanced or metastatic UC who had received platinum-based chemotherapy were treated with an outpatient gemcitabine and paclitaxel combination regimen.
  • Patients were evaluated after every 2 cycles of therapy using computed tomography.
  • RESULTS: Of the 33 patients enrolled in this study, 30 could be evaluated to determine treatment efficacy; 10 had an objective response [overall response rate: 33.3%, 95% confidence interval (CI), 19.2-51.2%].
  • The chemotherapy sensitivity differed with disease site.
  • The response rates of lung and bone metastases were 27% and 14%, and the progressive disease (PD) rates of lung and bone metastases were 13% and 14%, respectively.
  • CONCLUSIONS: Gemcitabine and paclitaxel combination therapy is a tolerable and active regimen for patients with advanced UC after failure of platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / mortality. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Paclitaxel / administration & dosage. Peripheral Nervous System Diseases / chemically induced. Prognosis. Survival Rate. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211575.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Giglio P, Gilbert MR: Neurologic complications of cancer and its treatment. Curr Oncol Rep; 2010 Jan;12(1):50-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic complications of cancer and its treatment.
  • The central nervous system (CNS) and peripheral nervous system (PNS) are very susceptible to cancer and its treatment.
  • The most direct involvement of the nervous system manifests in the development of primary brain and spinal cord tumors.
  • Many cancers exhibit a propensity toward spread to the CNS, and brain metastases are common problems seen in malignancies such as lung, breast, and melanoma.
  • In some cases, cancer has sudden, devastating effects on the nervous system: epidural spinal cord compression or cord transection from pathologic fractures of vertebra involved by cancer; increased intracranial pressure from intracranial mass lesion growth and edema; and uncontrolled seizure activity as a result of intracranial tumors (status epilepticus), which are neuro-oncologic emergencies.
  • The best known indirect or remote effects of cancer on the nervous system are the neurologic paraneoplastic syndromes.
  • Treatment of cancer can have neurologic complications.
  • The commonest of these complications are radiation-induced injury to the brain, spine, and peripheral nerves and chemotherapy-induced peripheral neuropathy.
  • The suppressant effect of cancer and its treatment on the body's immune system can result in infectious complications within the nervous system.

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1985 Jan;35(1):8-15 [2981417.001]
  • [Cites] Medicine (Baltimore). 1985 Jan;64(1):16-35 [3965856.001]
  • [Cites] Arch Neurol. 1988 Jul;45(7):741-4 [3390029.001]
  • [Cites] Neurology. 1989 Jun;39(6):789-96 [2725874.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2919-31 [7773943.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):543-8 [8630963.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17(10):1932-6 [8933882.001]
  • [Cites] Arch Neurol. 1997 Jan;54(1):16-7 [9006407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Skeletal Radiol. 1997 May;26(5):284-8 [9194228.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2522-7 [9667273.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):135-40 [9696363.001]
  • [Cites] Neurology. 1999 Jan 1;52(1):216-7 [9921888.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Head Neck. 2005 Mar;27(3):187-94 [15627248.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):5-14 [16215811.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Nov;13(11):1369-79 [17950923.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Feb;29(2):400-2 [18272570.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):599-601 [18304968.001]
  • [Cites] Lancet Neurol. 2008 Apr;7(4):327-40 [18339348.001]
  • [Cites] Curr Oncol Rep. 2008 Jan;10(1):72-7 [18366963.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(11):1507-15 [18571399.001]
  • [Cites] Oncologist. 2008 Sep;13(9):967-77 [18776058.001]
  • [Cites] Rinsho Shinkeigaku. 2008 Nov;48(11):871-4 [19198103.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7 [19034447.001]
  • [Cites] Front Neurol Neurosci. 2009;26:120-5 [19349709.001]
  • [Cites] J Neuroimaging. 2009 Jul;19(3):274-6 [18681929.001]
  • [Cites] Semin Oncol. 2009 Aug;36(4 Suppl 2):S35-45 [19660682.001]
  • [Cites] Arch Neurol. 2009 Sep;66(9):1174-5 [19752313.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Oct;6(10):596-603 [19707193.001]
  • [Cites] Lancet Oncol. 2009 Nov;10(11):1037-44 [19801201.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):225-9 [2086737.001]
  • [Cites] Neurology. 1991 Nov;41(11):1765-9 [1944906.001]
  • [Cites] Bone. 1991;12 Suppl 1:S9-10 [1954049.001]
  • [Cites] Neurol Clin. 1991 Nov;9(4):857-66 [1722001.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):268-73 [1637135.001]
  • [Cites] Neurology. 1995 Mar;45(3 Pt 1):421-7 [7898688.001]
  • [Cites] Neurology. 2000 Mar 28;54(6):1222-6 [10746588.001]
  • [Cites] Radiographics. 2000 Jul-Aug;20(4):1023-32 [10903692.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):120-3 [11550307.001]
  • [Cites] Bone Marrow Transplant. 2002 Jun;29(12):963-5 [12098063.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] Neurologist. 2003 Jul;9(4):180-8 [12864928.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):363-8 [12872358.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):138-43 [4272658.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9 [6154024.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Scand J Haematol. 1985 Nov;35(5):487-96 [4089528.001]
  • (PMID = 20425608.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA127001-02; United States / NCI NIH HHS / CA / P50 CA127001; United States / NCI NIH HHS / CA / P50 CA127001-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  • [Other-IDs] NLM/ NIHMS172362; NLM/ PMC3637950
  •  go-up   go-down


9. Kinebuchi Y, Noguchi W, Igawa Y, Nishizawa O: Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol; 2005 Oct;10(5):353-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy.
  • A 25-year-old man was referred to our hospital with left flank pain, and computed tomography (CT) and magnetic resonance imaging (MRI) revealed large retroperitoneal masses.
  • Physical examination revealed many café-au-lait spots and superficial neurofibromas, and a diagnosis of neurofibromatosis type 1 (von Recklinghausen's disease) was made.
  • The tumor was resected, and the pathological diagnosis was malignant peripheral nerve sheath tumor (MPNST).
  • Six months after the operation, lung metastases were detected.
  • He received four courses of chemotherapy with carboplatin and etoposide, and the metastatic lung lesions were markedly decreased.
  • After chemotherapy, complete resection of the remaining lung lesions was performed, and there has been no recurrence to date.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nerve Sheath Neoplasms / drug therapy. Neurofibromatosis 1 / complications. Peripheral Nervous System Neoplasms / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):627-30 [11956640.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1552-4 [12737880.001]
  • [Cites] Ear Nose Throat J. 2003 Nov;82(11):862-5 [14661436.001]
  • [Cites] Urology. 1985 Sep;26(3):209-17 [3929440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Radiographics. 2003 May-Jun;23 (3):790-4 [12740477.001]
  • (PMID = 16247664.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • Two patients suffered from Neurofibromatosis type 1.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • INTERPRETATION: MPNST is a rare and fatal diagnosis in neurosurgery with high risk of local recurrence and occurence of distant metastases.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


11. Choi HS, Koh SH, Park ES, Shin HY, Ahn HS: CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma. Pediatr Blood Cancer; 2005 Jul;45(1):68-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma.
  • We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34(+) peripheral blood stem cell transplantation (PBSCT).
  • Fifteen stage 4 NBL patients underwent CD34(+) transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan.
  • There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4-7 months after CD34(+) transplantation.
  • CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies.
  • [MeSH-major] Antigens, CD34. Brain Neoplasms / secondary. Neuroblastoma / secondary. Neuroblastoma / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Incidence. Infant. Korea / epidemiology. Male. Risk


12. Yone K, Ijiri K, Hayashi K, Yokouchi M, Takenouchi T, Manago K, Nerome Y, Ijichi O, Ikarimoto N, Komiya S: Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report. Spinal Cord; 2004 Mar;42(3):199-203
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report.
  • STUDY DESIGN: A case report of primary malignant peripheral nerve sheath tumor (MPNST) of the cauda equina in a child is presented, and the literature is reviewed.
  • OBJECTIVE: To discuss the problems involved in the treatment of primary intradural MPNSTs.
  • RESULTS: Although adjuvant chemotherapy was administered local recurrence and cerebral and spinal metastases of the tumor were found 6 months after the operation.
  • Following additional incomplete removal of the recurrent tumor, radiation therapy was administered.
  • Although recurrent and metastatic tumors disappeared or diminished in size by radiation, tumors increased in size thereafter, despite additional adjuvant chemotherapy.
  • Although no gold standard for the treatment of tumors has been established yet, surgical removal of tumors combined with postoperative high-dose radiation may be recommended.
  • [MeSH-major] Cauda Equina / pathology. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15001982.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Hara T, Hirano M, Nozawa H, Nakada K, Hirano Y, Oyama K, Hada T, Takagi T, Kikkawa H: [A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy]. Gan To Kagaku Ryoho; 2005 Jun;32(6):829-31
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 48-year-old man underwent subtotal esophagectomy for pStage III (pT 3 pN 3) thoracic esophageal carcinoma on June 20, 2002, in combination with chemotherapy (5-FU 500 mg/day day 1-14, CDDP 10 mg/day day 1-14, VDS 3 mg on days 1 and 8) before and after the operation.
  • Chemo (same regimen)-radiotherapy (50 Gy) was then performed but without effect.
  • Thereafter, lung and upper mediastinal metastases were found, and weekly administration of paclitaxel (70 mg/m2, day 1, 8, 15, q 4w) was initiated in combination with radiotherapy (40 Gy).
  • Two cycles of treatment resulted in PR, and CR was achieved after the 8th cycle was completed.
  • Although treatment was terminated after the 12 th cycle due to development of peripheral neuropathy (grade 2), CR was still maintained 8 months after the completion of treatment.
  • These results suggested the effectiveness of the treatment in cases that show resistance to conventional 5-FU-based chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Esophagectomy. Humans. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Radiotherapy Dosage. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984525.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Takashima T, Ito T, Sato T, Hirata K: [A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1103-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of recurrent gastric cancer with peritoneal dissemination and paraaortic lymph node metastases, successfully treated with weekly administration of paclitaxel.
  • The patient was a 63-year-old man who underwent distal gastrectomy with lymph node dissection for advanced gastric cancer in February 2005.
  • After the operation, adjuvant chemotherapy with S-1 was started and continued.
  • Grade 1 peripheral neuropathy and grade 2 leukocytopenia were noted, but no serious adverse reaction appeared.
  • Weekly administration of PTX may be a promising regimen as second-line chemotherapy for S-1-resistant recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Drug Resistance, Neoplasm. Oxonic Acid. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Leukopenia / chemically induced. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol; 2008 Apr 10;26(11):1830-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
  • PURPOSE: Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection.
  • PATIENTS AND METHODS: Fifty-six patients with metastatic CRC with liver metastases potentially curable by resection were eligible for this single-center, nonrandomized phase II trial.
  • The sixth cycle of therapy did not include bevacizumab, resulting in 5 weeks between the last administration of bevacizumab and surgery.
  • RESULTS: Objective response to neoadjuvant chemotherapy was achieved in 41 patients (73%).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Capecitabine. Chemotherapy, Adjuvant. Diarrhea / chemically induced. Drug Administration Schedule. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Liver Regeneration / drug effects. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Aug 1;26(22):3812-3; author reply 3813 [18669474.001]
  • (PMID = 18398148.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Lurain JR: Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med; 2002 Jun;47(6):451-9
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multimodality therapy with combination chemotherapy employing etoposide, high-dose methotrexate, actinomycin D, cyclophosphamide and vincristine and adjuvant radiotherapy and surgery, when indicated, has resulted in cure rates of 80-90% in patients with high-risk metastatic gestational trophoblastic tumors.
  • However, 25-30% of high-risk patients will have an incomplete response to first-line chemotherapy or will relapse from remission.
  • Most of these patients will have a clinicopathologic diagnosis of choriocarcinoma, multiple metastases to sites other than the lung and vagina, and failed or inappropriate previous chemotherapy, resulting in very high World Health Organization scores.
  • Salvage chemotherapy with cisplatin/etoposide, usually in conjunction with bleomycin or ifosfamide, as well as surgical resection of sites of resistant disease in selected patients, will result in a cure for most patients.
  • Colony-stimulating factors should be used to prevent treatment delays and dose reductions.
  • Newer anticancer agents, such as paclitaxel and gemcitibine, and high-dose chemotherapy with or without autologous bone marrow transplantation or peripheral blood stem cell support may play a role in the future management of selected patients.
  • [MeSH-major] Gestational Trophoblastic Disease / therapy. Pregnancy, High-Risk
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Central Nervous System Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Hysterectomy. Liver Neoplasms / secondary. Neoplasm Staging / methods. Neoplasm Staging / standards. Patient Selection. Pregnancy. Pregnancy Outcome. Radiotherapy, Adjuvant. Remission Induction. Risk Factors. Salvage Therapy / methods. Stem Cell Transplantation. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12092013.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


17. Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki S, Souglakos J, Mavromanomakis E, Vlachonikolis J, Georgoulias V: Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis. Cancer; 2000 Sep 15;89(6):1380-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The quantitative abnormalities of the different peripheral blood lymphocyte subsets during docetaxel administration were prospectively studied.
  • METHODS: Forty-six chemotherapy-naive patients with solid tumors were treated with docetaxel either in a 3 weekly (n = 33) or weekly (n = 13) schedule.
  • Twenty patients with central nervous system (CNS) metastatic disease as the first clinical presentation of cancer and 35 patients with metastatic colorectal carcinoma treated with chemotherapy were enrolled as controls.
  • The phenotype of peripheral blood lymphocytes was determined by indirect immunofluorescence using appropriate monoclonal antibodies and fluorescent-activated cell sorter analysis.
  • RESULTS: After the administration of the first docetaxel cycle, the absolute number of peripheral blood lymphocytes (P < 0.005), CD3(+) (P < 0.01), CD4(+) (P < 0.01), CD8(+) (P < 0.01), and CD56(+) (P < 0.
  • Further treatment resulted in a further decrease of these lymphocyte subsets including CD20(+) cells (P < 0.01).
  • The administration of either high dose corticosteroids in patients with CNS metastases or an irrelevant chemotherapy (CPT-11/5-FU) did not result in similar abnormalities.
  • Eight (17%) patients developed nonneutropenic infections during docetaxel treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Lymphocytes / drug effects. Lymphopenia / chemically induced. Paclitaxel / adverse effects. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Clinical Trials as Topic. Female. Humans. Immunophenotyping. Infection / etiology. Lymphocyte Count / drug effects. Lymphocyte Subsets / drug effects. Lymphocyte Subsets / immunology. Male. Middle Aged. Neoplasms / blood. Neoplasms / drug therapy. Neutropenia / blood. Neutropenia / chemically induced. Neutropenia / immunology. Neutrophils / cytology. Neutrophils / drug effects. Prospective Studies

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11002234.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T: [Olfactory neuroblastoma with spinal metastasis: case report]. No Shinkei Geka; 2007 May;35(5):503-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of olfactory neuroblastoma with cauda equina metastases.
  • Whole-spine irradiation of 32 Gy and lumber-spine irradiation of 10 Gy were performed.
  • However, effectiveness of chemotherapy was still uncertain.
  • Radiotherapy and further treatment including chemotherapy should be considered in case of spinal metastasis.
  • [MeSH-major] Cauda Equina. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491347.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Beck A, Jonas J, Frenzel H, Bähr R: [Gastrointestinal autonomic nerve tumor]. Zentralbl Chir; 2001 Sep;126(9):702-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within the follow-up of 29 months metastases appeared within the omentum majus with a diffuse peritoneal spreading.
  • Several trials of adjuvant chemotherapy (adriamycine/ifosamide, taxotere, gemcitabine/xyloda) were ineffective.
  • Since there is no option for medical treatment, surgical resection is the treatment of choice and has to be considered also in the case of recurrence.
  • [MeSH-major] Autonomic Nervous System Diseases / surgery. Ileal Neoplasms / surgery. Ileum / innervation. Jejunal Neoplasms / surgery. Jejunum / innervation. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Autonomic Nervous System / pathology. Combined Modality Therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699287.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Huang F, Alrefae M, Langleben A, Roberge D: Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):752-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prophylactic cranial irradiation (PCI) has a well-recognized role in the treatment of leukemia and small-cell lung cancer.
  • METHODS AND MATERIALS: In reviewing our experience with PCI as part of a complex protocol for advanced breast cancer, we present descriptive data on late central nervous system outcomes in those receiving PCI.
  • After high-dose anthracycline-based induction chemotherapy, Stage IIIB/IV breast cancer responders underwent tandem autologous marrow transplantation.
  • Whole-brain radiotherapy was delivered by usual means, at 36 Gy in 20 fractions.
  • Disease was largely metastatic (79%), and 75% were previously exposed to chemotherapy or hormonotherapy.
  • Six patients developed brain metastases, 2 despite PCI.
  • CONCLUSIONS: We present a series of advanced breast cancer patients treated prophylactically with whole-brain radiotherapy following an aggressive chemotherapy regimen.
  • Although the therapeutic benefit of PCI is not ascertainable here, we describe brain metastases occurring despite PCI and serious long-term neurobehavioral sequelae in PCI-treated patients.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Clinical Protocols. Cognition Disorders / etiology. Combined Modality Therapy / methods. Fatal Outcome. Female. Humans. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction


21. Mir O, Alexandre J, Ropert S, Montheil V, Martin I, Durand JP, Goldwasser F: Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anticancer Drugs; 2009 Feb;20(2):105-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many patients with stage IV nonsmall cell lung cancer (NSCLC) are unfit for cisplatin-based chemotherapy because of poor performance status, impaired renal function or severe comorbidity.
  • Twenty-two patients (40%) had two or more metastatic sites, and 14 (25%) had central nervous system metastases.
  • The main grade 3/4 toxicities were: neutropenia (15 patients, 27%), anaemia (12 patients, 22%) and peripheral neuropathy (eight patients, 15%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Organoplatinum Compounds / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209026.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


22. Kaan TK, Yip PK, Patel S, Davies M, Marchand F, Cockayne DA, Nunn PA, Dickenson AH, Ford AP, Zhong Y, Malcangio M, McMahon SB: Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain; 2010 Sep;133(9):2549-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pain remains an area of considerable unmet clinical need, and this is particularly true of pain associated with bone metastases, in part because existing analgesic drugs show only limited efficacy in many patients and in part because of the adverse side effects associated with these agents.
  • A peripheral site of action was also suggested by studies on the extracellular release of adenosine triphosphate from MRMT-1 carcinoma cells.
  • These data suggest that blockade of P2X3 and P2X2/3 receptors on both the peripheral and central terminals of nocioceptors contributes to analgesic efficacy in a model of bone cancer pain.
  • Thus, systemic P2X3 and P2X2/3 receptor antagonists with central nervous system penetration may offer a promising therapeutic tool in treating bone cancer pain.
  • [MeSH-major] Pain / drug therapy. Pain / psychology. Purinergic P2 Receptor Antagonists. Pyrimidines / therapeutic use
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Administration, Oral. Amidines. Animals. Bone Neoplasms / complications. Bone Neoplasms / pathology. Calcitonin Gene-Related Peptide / metabolism. Carcinoma / complications. Carcinoma / pathology. Cells, Cultured. Coculture Techniques / methods. Disease Models, Animal. Dose-Response Relationship, Drug. Extracellular Signal-Regulated MAP Kinases / metabolism. Ganglia, Spinal / cytology. Hyperalgesia / drug therapy. Pain Measurement. Rats. Rats, Sprague-Dawley. Receptors, Purinergic P2 / metabolism. Receptors, Purinergic P2X2. Receptors, Purinergic P2X3. Sensory Receptor Cells / drug effects. Sensory Receptor Cells / physiology. X-Ray Microtomography / methods

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802203.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501617; United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amidines; 0 / P2rx2 protein, rat; 0 / P2rx3 protein, rat; 0 / Purinergic P2 Receptor Antagonists; 0 / Pyrimidines; 0 / RO-4 compound; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X2; 0 / Receptors, Purinergic P2X3; 0 / diamidino compound 253-50; 83652-28-2 / Calcitonin Gene-Related Peptide; 8L70Q75FXE / Adenosine Triphosphate; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


23. Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T, Schmidt-Wolf IG: Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol; 2002 Apr;13(4):629-31
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelosuppression was found to be dose-limiting, but peripheral neurotoxicity is also a well known side-effect.
  • Central nervous system toxicity is rare, probably because paclitaxel does not cross the blood-brain barrier.
  • Computer tomography and magnetic resonance imaging showed no evidence of cerebral metastases.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056715.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement